Semaglutide and tirzepatide were not designed to affect hair, but the way they work indirectly puts hair follicles at risk. GLP-1 receptor agonists suppress appetite and slow gastric emptying, which commonly leads to rapid, substantial weight loss: often 15–20% of total body weight within a year.^2,4 This kind of fast weight loss is a significant physiological stressor, and the hair follicle is exquisitely sensitive to metabolic stress.

The dominant mechanism identified across the medical literature is telogen effluvium, a diffuse, non-scarring shedding condition. Hair normally cycles through three phases: the anagen (growth) phase, the catagen (transitional) phase, and the telogen (resting/shedding) phase. Acute stress on the body, from rapid weight loss, caloric restriction, or nutritional deficiency, can prematurely push a large percentage of hair follicles from the growth phase into the shedding phase at once, producing the diffuse thinning many GLP-1 patients notice roughly two to three months after starting therapy or after their most rapid period of weight loss.^1,3

A 2025 systematic review in the International Journal of Dermatology confirmed that among GLP-1 receptor agonists, semaglutide and tirzepatide showed the highest reported incidence of hair loss, with telogen effluvium and androgenetic alopecia (AGA) identified as the predominant subtypes. Tirzepatide, which produces the greatest average weight loss, was most frequently linked to telogen effluvium specifically.¹

Beyond the weight-loss stress response, researchers have proposed several contributing mechanisms:

• Hormonal shifts, changes in insulin and insulin-like growth factor (IGF-1) signaling during rapid weight loss, may influence androgen activity and accelerate androgenetic alopecia in genetically predisposed patients.¹
• Nutritional deficiency, reduced caloric and protein intake along with lower levels of key micronutrients such as vitamin D, iron, and zinc, can directly impair the hair growth cycle.¹
• Psychosocial and metabolic stress, the physiological burden of adapting to a new medication and a changing body composition, can itself be a shedding trigger.¹
• Direct receptor effects, more speculative research has explored GLP-1 receptor expression in dermal fibroblasts and adipose-derived stem cells, theorizing that receptor activation could alter local cytokine signaling in the scalp, though this remains an active area of investigation rather than established fact.³

Importantly, hair loss is not listed as a common side effect in the original semaglutide prescribing information, but pharmacovigilance data and post-marketing reports have made the association increasingly clear. In clinical trials of Wegovy, alopecia was reported in about 3% of adult patients on the medication versus 1% on placebo.⁷

With roughly one in eight U.S. adults now reporting having used a GLP-1 medication for weight loss, diabetes, or both, hair loss has moved from an anecdotal complaint to a formally studied adverse event.⁴ A large 2025 scoping review identified hair loss as an "emerging" adverse effect worth systematic investigation, noting that most existing studies lack formal dermatologic diagnostic confirmation, meaning real-world prevalence is likely underreported.³ Wegovy's own clinical trial data reported alopecia in about 3% of adult users compared to 1% of those on placebo, and in adolescent patients, 4% versus 0%.⁷ While that makes hair shedding far less common than nausea or gastrointestinal symptoms, it is frequently discussed within online weight-loss communities and is one of the more common reasons patients in Newport Beach and Orange County are now seeking evaluation for hair restoration alongside their weight-loss treatment.

The good news: GLP-1-associated telogen effluvium is usually temporary, and there is a well-established toolkit of medical and regenerative options to support regrowth while you continue your weight-loss journey. Dr. Rob Berberian builds individualized treatment plans for patients throughout Newport Beach, Orange County, Los Angeles, and California combining the following approaches.

1. Topical & Oral Medications

Minoxidil remains the most widely studied first-line medical therapy for hair loss. Available in topical and oral (low-dose) form, minoxidil works by prolonging the anagen (growth) phase and increasing blood flow to the follicle, and it is frequently recommended as a foundation therapy for patients experiencing telogen effluvium or androgenetic alopecia while on GLP-1 medications.¹³

2. Platelet-Rich Plasma (PRP)

PRP therapy uses a concentrated preparation of your own blood platelets, rich in growth factors like EGF, IGF-1, and VEGF, injected directly into the scalp to stimulate dormant follicles. A randomized controlled trial in women with androgenetic alopecia found that 57% of PRP-treated patients showed clinical improvement at 24 weeks compared to just 7% in the placebo group, with statistically significant increases in hair density at both 8 and 24 weeks.¹¹ A 2023 meta-analysis of nine randomized trials confirmed that PRP significantly increases hair density at 3 and 6 months compared to placebo.¹²

3. Exosome Hair Injections

Exosome therapy is one of the newer, most talked-about regenerative options in hair restoration. Exosomes are cell-derived nanovesicles carrying growth factors and signaling molecules that can stimulate dermal papilla cells and activate hair follicle stem cells. A 2023 systematic review in the Journal of Cosmetic Dermatology found preclinical and early clinical evidence supporting exosome therapy's potential for hair regrowth, while noting that further large-scale clinical trials are still needed to fully define its long-term efficacy.⁹ Dr. Rob Berberian offers Exosome Hair Restoration in Newport Beach as a non-surgical option, often combined with PRP or FUE for enhanced results.

4. Non-Surgical Solutions & Supplements

Nutritional support is essential during GLP-1 therapy, since appetite suppression can lead to inadequate protein and micronutrient intake. Dr. Rob Berberian frequently recommends hair-targeted supplementation (biotin, iron, vitamin D, zinc, and amino acids as clinically indicated), along with dermatologist-recommended non-surgical hair loss solutions for men and women available directly through the practice.

5. FUE Hair Transplant (Surgical)

For patients with more advanced thinning, established androgenetic alopecia, or hair loss that hasn't fully responded to medical therapy, Follicular Unit Extraction (FUE) hair transplant remains the gold-standard surgical option. See the full breakdown of the FUE process, downtime, and cost below.

Whether you're managing GLP-1-related shedding, recovering from a hair transplant, or maintaining results from PRP or Exosome therapy, proper aftercare is critical for long-term success:

• Use organic, sulfate-free shampoo and natural hair care products. Harsh, sulfate-heavy formulas can strip the scalp barrier and irritate follicles that are already under stress. Gentle, natural cleansers support a healthier scalp environment for regrowth.
• Prioritize protein and key micronutrients (iron, vitamin D, zinc, biotin), especially important while appetite is suppressed on a GLP-1 medication.
• Stay consistent with topical or oral minoxidil if prescribed, stopping and starting repeatedly reduces its effectiveness.
• Schedule maintenance PRP or Exosome sessions as recommended, these regenerative therapies work best as a series rather than a single treatment, and periodic maintenance sessions help sustain density over time.
• Avoid tight hairstyles, excessive heat styling, and aggressive brushing during periods of active shedding.
• Never stop a GLP-1 medication abruptly due to hair loss concerns without first speaking with your prescribing physician.
• Follow all post-procedure instructions closely after any FUE hair transplant, PRP, or Exosome session, including activity restrictions and scalp care during the initial healing window.